OSONG, South Korea: The Sarawak Biodiversity Council and the Osong Medical Innovation Foundation (KBIOHealth) have signed a Memorandum of Understanding (MoU) to strengthen cooperation in biotechnology.
The partnership will focus on joint research and development (R&D), regulatory collaboration, and compliance with ‘Good Manufacturing Practice’ (GMP) standards.
The MoU was signed by Council Chairman and Deputy Sarawak Secretary, Datuk Seri Dr Muhammad Abdullah Zaidel, and KBIOHealth Chairman and Chief Executive Officer, Lee Myung-su, at an event held recently at the Osong Medical Innovation Foundation Complex.
Muhammad Abdullah said the collaboration aims to work together with KBIOHealth on joint R&D for pre-clinical testing and the production of bioproducts.
“Today’s MoU benefits both the Sarawak Biodiversity Centre and KBIOHealth,” he said at the event.
Meanwhile Lee hoped that through the MoU, it will develop international industry ties and further advance their cooperation.
The collaboration is seen as a milestone in Sarawak’s efforts to build a competitive biotechnology ecosystem and expand its role in the global bioeconomy.
The event also featured a working visit to KBIOHealth’s world-class facilities, including the New Drug Development Centre, Non-Clinical Evaluation, and Biopharmaceutical Manufacturing Centre.
KBIOHealth is a leading public institution in South Korea dedicated to advancing biomedical innovation.
Located in the Osong High-Tech Medical Complex in North Chungcheong Province, it provides services in pre-clinical testing, regulatory support, and GMP biomanufacturing.
Since 2022, it has also offered specialised biopharma training programmes to develop skilled talent and strengthen the sector.
